Vanesa Matías del Pozo

Vanesa Matías del Pozo

Auto-generated profile, based on publicly available information

Vanesa Matías del Pozo

Department of Paediatrics, Faculty of Medicine, Valladolid University, Valladolid, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2022 in Infection
Verified
Journal Article
Open access
PDF file
LBLorena Bermúdez Barrezueta
Lorena Bermúdez Barrezueta
VPVanesa Matías Del Pozo
Vanesa Matías Del Pozo
PLPablo López-Casillas
Pablo López-Casillas
MRMarta Brezmes Raposo
Marta Brezmes Raposo
MZMaría Gutiérrez Zamorano
María Gutiérrez Zamorano
MVMaría de la Asunción Pino Vázquez
María de la Asunción Pino Vázquez
Background: The COVID-19 pandemic has caused a variation in the circulation of common respiratory viruses. Our objective was to analyse the epidemiology of respiratory syncytial virus (RSV) bronchiolitis admissions during the COVID-19 pandemic in comparison with previous epidemic seasons. Methods: We conducted an observational study involving infants with RSV bronchiolitis admitted to a tertiary hospital during two periods: pandemic COVID-19 (15 March 2020–30 September 2021) and pre-pandemic (1 October 2014–14 March 2020). Demographic and clinical characteristics were collected. Results: A total of 270 patients were admitted for RSV bronchiolitis: 253 in the pre-pandemic period with an average of 42 admissions per season vs 17 in the pandemic. During the pandemic, the RSV outbreak started late in June 2021 with a higher percentage of prematurity and PICU admissions. Conclusion: A change in RSV seasonality was observed during the COVID-19 pandemic, with an unusual outbreak in summer 2021 of lower magnitude than previous seasons.

7 January 2025 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
MMMaría Medina Muñoz
María Medina Muñoz
Mario Cantó CerdánMario Cantó Cerdán
Mario Cantó Cerdán
VPVanesa Matías del Pozo
Vanesa Matías del Pozo
AVAsunción Pino Vázquez
Asunción Pino Vázquez
AAAndres Jose Alcaraz
Andres Jose Alcaraz
PTPedro Juan Tárraga-López
Pedro Juan Tárraga-López

16 May 2025 in European Journal of Pediatrics
Verified
Journal Article
Open access
LBLorena Bermúdez-Barrezueta
Lorena Bermúdez-Barrezueta
VPVanesa Matías del Pozo
Vanesa Matías del Pozo
JMJose Manuel Marugán-de-Miguelsanz
Jose Manuel Marugán-de-Miguelsanz
ELElena Infante López
Elena Infante López
PUPilar Uribe-Reina
Pilar Uribe-Reina
MPMaría Asunción Pino-Vázquez
María Asunción Pino-Vázquez
The aim of this study was to assess the impact of universal nirsevimab administration on hospitalisations and paediatric intensive care unit (PICU) admissions due to lower respiratory tract infection associated with respiratory syncytial virus (RSV-LRTI). An observational study was conducted at a tertiary hospital in Spain to compare the frequency and characteristics of children under five years of age hospitalised for RSV-LRTI between October 2023 and March 2024 (nirsevimab period), with the data from two prepandemic COVID- 19 seasons (2018–2019 and 2019–2020) and one postpandemic season (2022–2023). A total of 311 patients were included in the study. During the nirsevimab period, a decrease in the number of children hospitalised for RSV-LRTI was observed, particularly for children under six months of age. Compared with the prepandemic period, there was an 83.3% decrease in hospitalisations and a 73.3% reduction in PICU admissions in this age group. Similarly, compared with the postpandemic period, there was a 90.8% reduction in hospitalisations and an 87.9% reduction in PICU admissions. Furthermore, the median age was greater (15.6 months; IQR 11.1–27.3) than it was in the prepandemic period (4 months; IQR 1.6–8.9) and postpandemic period (3.4 months; IQR 1.5–10.6) (p < 0.001). Moreover, the length of hospital stay during the nirsevimab period (4 days; IQR 3–6) was shorter than that observed during the prepandemic period (6 days; IQR 4–9) and the postpandemic period (5 days; IQR 3–8) (p = 0.003). Conclusions: Following the introduction of universal immunoprophylaxis with nirsevimab, notable reductions in hospitalisations and PICU admissions due to RSV-LRTI were observed among young infants. This resulted in a shift in the age profile and a shorter length of hospital stay. What Is Known• Nirsevimab is a novel humanised IgG1 monoclonal antibody with a prolonged half-life that has been demonstrated to reduce RSV-associated hospitalisations in controlled clinical trials; however, real-world data are still limited. What Is New:• The findings of the present study corroborate the effectiveness of nirsevimab. Following the implementation of universal immunoprophylaxis with nirsevimab, a notable reduction in hospitalisations and admissions to the paediatric intensive care unit for RSV-associated lower respiratory tract infections was observed, particularly among infants younger than 6 months, who have been the main target of this passive immunisation strategy. In addition, the patients admitted were older and the length of hospital stay was shorter.

24 November 2023 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
CPCarlos Pita-Martínez
Carlos Pita-Martínez
CGCarmen Goez-Sanz
Carmen Goez-Sanz
AVAna Virseda-Berdices
Ana Virseda-Berdices
AGAlejandro Gonzalez-Praetorius
Alejandro Gonzalez-Praetorius
EMEsther Mazario-Martín
Esther Mazario-Martín
IMIsidoro Martinez
Isidoro Martinez
We aimed to analyze whether the expression of inflammatory and antiviral genes in respiratory syncytial virus (RSV)-infected infants' peripheral blood is associated with bronchiolitis progression. We conducted a prospective study on 117 infants between 2015 and 2023. The expression levels of nine genes were quantified by quantitative polymerase chain reaction. Infants were classified according to their clinical evolution during hospital admission: (i) non-progression (n = 74), when the RSV bronchiolitis severity remained stable or improved; (ii) unfavorable progression (n = 43), when the RSV bronchiolitis severity increased. The association analysis was performed by logistic regression, adjusted by age, gender, prematurity, and RSV bronchiolitis severity in the emergency room. Infants were 57.3% male, and the median age of the study population was 61 days. Thirty-five infants (30.7%) were admitted to the intensive care unit after hospital admission. Univariate logistic models showed that tumor necrosis factor (TNFα) and chemokine (C-C motif) ligand (CCL5) gene expression at baseline were inversely associated with unfavorable progression, which was confirmed by multivariate analyses: TNFα (adjusted odds ratio = 0.8 [95% confidence interval = 0.64-0.99], P-value = 0.038) and CCL5 (adjusted odds ratio = 0.76 [95% confidence interval = 0.62-0.93], P-value = 0.007). An inadequate immune response to RSV, characterized by reduced gene expression levels of CCL5 and TNFα in peripheral blood, was associated with an unfavorable progression of RSV bronchiolitis.